XERS
Xeris Biopharma Holdings Inc
NASDAQ · Pharmaceuticals
$7.01
+0.10 (+1.45%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 239.39M | 149.64M | 193.05M | 186.74M | 158.16M |
| Net Income | -64,639,302 | -36,364,152 | 59.12M | 58.69M | 48.77M |
| EPS | — | — | — | — | — |
| Profit Margin | -27.0% | -25.7% | 30.6% | 31.4% | 30.8% |
| Rev Growth | +60.0% | +60.0% | -5.7% | +1.9% | +8.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 488.43M | 488.43M | 380.75M | 375.14M | 369.70M |
| Total Equity | 118.00M | 118.00M | 540.65M | 620.44M | 584.53M |
| D/E Ratio | 4.14 | 4.14 | 0.70 | 0.60 | 0.63 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -24,862,600 | -14,764,014 | 68.71M | 67.69M | 55.43M |
| Free Cash Flow | — | — | 33.47M | 40.84M | 33.96M |